This piece by Ned Pagliarulo in BioPharma Dive is a great primer on our recently announced collaboration with ARTBIO and the excitement surrounding #radiopharmaceuticals overall. As Ned writes, “The radiopharma field is booming, drawing substantial investment from large companies and venture capital firms eager to capitalize on the drugs’ potential to balance cancer-killing potency with better safety.” The Helicon-enabled radioligand therapies we will co-develop will benefit from the hyper-tunability of Helicons, to control the drugs’ distribution and half-life, and from the uniqueness of lead-212, one of the most promising isotopes for radiopharmaceutical use. Check out this photo of our teams together kicking off our partnership, and read the story here: https://bit.ly/3KN2zm5 #radioligandtherapy #cancer #oncology #peptides #Helicons #patients
FogPharma’s Post
More Relevant Posts
-
Welcome our fantastic sponsor partners Volition | Proteome Sciences plc | Biocytogen | Veracyte, Inc. | EpigenDx, Inc. | GemPharmatech who are integral to the success of the Immuno-Oncology Conference at Double Tree by Hilton, San Diego - Mission Valley! Explore their contributions at the exhibition area, where they're showcasing the latest innovations that are shaping the future of cancer research. #sponsorappreciation #conferencepartnerships #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets #NextGenIO #marketsandmarketsconferences
To view or add a comment, sign in
-
At Pfizer, we are advancing a deep and diverse pipeline that spans three core scientific modalities to attack cancer from multiple angles, including more than 25 new molecular entities. Today at #ASCO24, we are excited to share updated Phase 1 data for several of our priority pipeline therapies, including an oral presentation on our promising investigational integrin beta-6-directed ADC in #NSCLC, which initiated a Phase 3 trial this year. We’re also sharing updated results for our potential first-in-class KAT6 inhibitor in ER+, HER2- metastatic #breastcancer, which were also published in Nature Medicine. Read more here: https://lnkd.in/gA9Y3QA6
To view or add a comment, sign in
-
🔎 Discover the power behind our platform! 🔍 In our recent R&D webinar, we discussed how our proprietary platform, secured by multiple IP families, is revolutionizing cancer therapy. To the best of our knowledge, Heidelberg Pharma AG is the only company worldwide developing amanitin as a novel payload for antibody-drug conjugates (#ADCs). Our robust IP strategy ensures a strong monopoly in this space, keeping competitors at bay. We've also successfully established a reliable supply chain for the GMP manufacturing of amanitin and amanitin-based ADCs. 📺 Watch the full recording to learn more about how our cutting-edge approach is setting new standards in cancer treatment: https://lnkd.in/eVJygzyn #ADC #ATAC #CancerResearch
To view or add a comment, sign in
-
🔍 Identify key characteristics of RTORs (endpoints, study design, clinical data, indication, time to approval, etc.) and how this has evolved over time. Visit our site for a free trial and demo to learn more → https://lnkd.in/dqzJEea4 #oncology #biotech #biotechnology #regulatoryaffairs #pharma #drugdevelopment #oncologytrials #oncologyresearch #cancer #oncology #regulatoryintelligence #regulatoryprecedent
To view or add a comment, sign in
-
Explore the top targets and the number of products in the bispecific antibody space with curated analytics by LARVOL CLIN. 🧬 Stay ahead with detailed insights into the evolving landscape of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechInsights #CancerData #Oncology
To view or add a comment, sign in
-
Ex- Summer Intern at Sun Pharmaceuticals, Gurugram || Student at Banasthali Vidyapith ll Pharmacy Student
Honored to participate in the 59th SPSR Webinar on Translational Phytomedicine for Cancer: Bridging Laboratory Research and Clinical Application' organized by the Society of Pharmaceutical Sciences and Research (SPSR) Special thanks to Monika Sabharwal ma'am, Dr. Lekshmi R. Nath ma'am and Pradeep Golani sir for their invaluable guidance and support. The session offered invaluable insights, Translating scientific discoveries from the lab into effective treatments for patients and how laboratory research can directly impact clinical practices in cancer treatment. #SPSR #Phytomedicine #CancerResearch #cancer #TranslationalMedicine"
To view or add a comment, sign in
-
With the American Association for Cancer Research (AACR) in full swing, among the many press releases and announcements there were two that stood out for me and my colleague Joel Sandler, Ph.D. – those from Candel Therapeutics and Vincerx Pharma. Both releases were for novel modalities. Both releases were preliminary results with limited data. Both releases announced, “Positive Interim/Preliminary Data”. In response, Candel’s share price shot up by nearly 300% (with initial after-hour trading reaching a stratospheric 500%!) while Vincerx cratered, losing nearly 80%. What happened? Please read on below for a full analysis. #oncology #AACR #oncologyresearch #biotech #biopharma #cancer #candeltx #vincerx
To view or add a comment, sign in
-
Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence
To view or add a comment, sign in
-
Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence
To view or add a comment, sign in
-
It’s here! Illumina’s flagship oncology assay, TruSight Oncology 500 HT, is now fully supported on our premier benchtop platforms, the NextSeq 1000 & 2000. Together, these solutions enable high-quality comprehensive genomic profiling for solid tumors on our most versatile and scalable benchtop instrument yet. Take advantage of: ✅ A fully verified and supported workflow ✅ Consistency with legacy instruments workflows ✅ Better economics with new XLEAP-SBS chemistry and consumables ✅ Faster sequencing times than NextSeq 550 ✅ Scalability from a benchtop platform at 8-36 samples per run ✅ Flexibility with the widest menu of applications from a benchtop platform Ready for the neXt LEAP in oncology research? To get started with TruSight Oncology 500 HT on the NextSeq 1000 & 2000 today, please contact your local representative. #Illumina #NGS #Oncology #CGP #PrecisionMedicine
To view or add a comment, sign in
11,840 followers
Helping Science & Technology companies find top talent through personalized recruitment solutions.
3moExciting collaboration, FogPharma! The partnership with ARTBIO in developing Helicon-enabled radioligand therapies marks a significant step forward in radiopharmaceuticals. Looking forward to seeing the innovations and impact in cancer treatment! 🌟 #Radiopharmaceuticals #Oncology #Innovation Recruits Lab (We're hiring)